Oncology
Basel, Switzerland
Anaveon is developing no-alpha IL-2 receptor agonists for the treatment of cancer.
It looks like you are using an older version of Internet Explorer which is not supported. We advise that you update your browser to the latest version of Microsoft Edge, or consider using other browsers such as Chrome, Firefox or Safari.